Zacks Investment Research Upgrades Anthera Pharmaceuticals (ANTH) to Buy

Zacks Investment Research upgraded shares of Anthera Pharmaceuticals (NASDAQ:ANTH) from a hold rating to a buy rating in a research report report published on Monday. They currently have $1.75 price target on the biopharmaceutical company’s stock.

According to Zacks, “Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company’s clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren’s Syndrome, Graves’ Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California. “

Separately, ValuEngine raised Anthera Pharmaceuticals from a strong sell rating to a sell rating in a research report on Sunday, December 31st.

Anthera Pharmaceuticals (NASDAQ:ANTH) opened at $1.59 on Monday. The firm has a market capitalization of $20.91, a PE ratio of -0.29 and a beta of 2.67. Anthera Pharmaceuticals has a 52-week low of $1.20 and a 52-week high of $6.24.

Anthera Pharmaceuticals (NASDAQ:ANTH) last released its earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.32. During the same period last year, the company earned ($4.85) earnings per share. research analysts predict that Anthera Pharmaceuticals will post -3.02 EPS for the current year.

An institutional investor recently raised its position in Anthera Pharmaceuticals stock. Wedbush Securities Inc. lifted its stake in shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) by 75.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 73,764 shares of the biopharmaceutical company’s stock after buying an additional 31,800 shares during the quarter. Wedbush Securities Inc. owned approximately 0.68% of Anthera Pharmaceuticals worth $106,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 16.10% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Zacks Investment Research Upgrades Anthera Pharmaceuticals (ANTH) to Buy” was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://www.com-unik.info/2018/02/08/zacks-investment-research-upgrades-anthera-pharmaceuticals-anth-to-buy.html.

Anthera Pharmaceuticals Company Profile

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Get a free copy of the Zacks research report on Anthera Pharmaceuticals (ANTH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit